Polycystic Ovary Syndrome
Conditions
Keywords
Polycystic ovary sybdrome, Taichi
Brief summary
The present study is a randomized pilot study, overweight/obese adolescent and young PCOS subjects will be assigned into two groups: Taichi arm and control arm. Hormonal profile and metabolic profile will be determined.
Interventions
BEHAVIORALTaichi
The program of Taichi training consisted of 60 minutes exercise sessions, 3 days per week for 12 weeks, based on their original level of physical activity. Each session comprised 40 minutes of Taichi training plus a 10-minute warm-up and cool-down. The Taichi training was instructed by the same experienced Taichi instructors who were qualified in the teaching of Taichi. The 24 forms of simplified Taichi recommended as the popular health sport by the General Administration of Sport of China were applied.
BEHAVIORALSelf-monitored exercise
Exercise was self-monitored and consisted of brisk walking, cycling, jogging, or any other aerobic exercise for 60 mins. 3 days per week for 12 weeks.
Sponsors
Heilongjiang University of Chinese Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
19 Years to 35 Years
Healthy volunteers
No
Inclusion criteria
* Women aged between 19 and 35 years; * Diagnosis of PCOS according to the modified Rotterdam criteria; * 2 years after menarche; * Body mass index (BMI) equal to or greater than 23 kg/m\*m.
Exclusion criteria
* Administration of other medications known to affect reproductive function or metabolism within the past three months, including oral contraceptives, Gonadotropin-releasing hormone (GnRH) agonists and antagonists, anti androgens, gonadotropins, anti-obesity drugs, Chinese herbal medicines, anti diabetic drugs such as metformin and thiazolidinediones, somatostatin, diazoxide, and calcium channel blockers. * Patients with other endocrine disorder including 21-hydroxylase deficiency, hyperprolactinemia, uncorrected thyroid disease, suspected Cushing's syndrome. * Patients with known severe organ dysfunction or mental illness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Body mass index (BMI) | 3 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fasting insulin (Ins) | 3 months | — |
| HOMA-IR | 3 months | HOMA-IR = fasting insulin concentrations (mIU/L) ×fasting plasma glucose concentrations (mmol/L)/22.5 |
| Testosterone (T) | 3 months | — |
| Fasting plasma glucose (Glu) | 3 months | — |
| Follicle stimulating hormone (FSH) | 3 months | — |
| Waist/hip ratio | 3 months | — |
| Ferriman-Gallwey score | 3 months | — |
| Luteinizing hormone (LH) | 3 months | — |
Countries
China
Outcome results
None listed